Regencell Bioscience Holdings (RGC) Cash & Current Investments (2020 - 2025)

Regencell Bioscience Holdings has reported Cash & Current Investments for 6 years, with the latest figure at $2.5 million in Q2 2025.

• For the quarter ending Q2 2025, Cash & Current Investments fell 68.88% year-over-year to $2.5 million; the trailing twelve-month figure through Jun 2024 stood at $8.0 million (down 31.16% YoY), and the FY2025 full-year result was $2.5 million, down 68.88% from the prior year.
• Cash & Current Investments for Q2 2025 stood at $2.5 million, down from $8.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $16.4 million in Q2 2022, with the low at $59413.0 in Q2 2021.
• Historically, Cash & Current Investments has averaged $7.7 million across 5 years, with a median of $8.0 million in 2024.
• Annual changes were most pronounced in 2021 — Cash & Current Investments slumped 84.65% — and 2022, when it surged 27532.0%.
• Regencell Bioscience Holdings' Cash & Current Investments stood at $59413.0 in 2021, then surged by 27532.0% to $16.4 million in 2022, then decreased by 29.56% to $11.6 million in 2023, then sank by 31.16% to $8.0 million in 2024, then plunged by 68.88% to $2.5 million in 2025.
• The last three Cash & Current Investments figures came in at $2.5 million (Q2 2025), $8.0 million (Q2 2024), and $11.6 million (Q2 2023), per Business Quant data.